Skip to main content
. Author manuscript; available in PMC: 2014 Jan 29.
Published in final edited form as: Sci Transl Med. 2013 Jul 24;5(195):195ra94. doi: 10.1126/scitranslmed.3006448

Fig. 5. Skewing potential of naïve CD4+ lymphocytes from LDS subjects and nonallergic controls after TGFβ stimulation.

Fig. 5

(A) Representative dot plot depicting expression of Foxp3 and IL-13 in LDS (n = 7) and nonallergic (NA; n = 4) CD4+ lymphocytes 4 days after naïve CD4+ T cells were cultured with increasing doses of recombinant TGFβ1 as indicated. (B) Percentage of IL-13–expressing Foxp3+ and Foxp3− cells in cultures from LDS patients (n = 7) compared to nonallergic controls (n = 4) after treatment with the indicated doses of recombinant TGFβ1. Significant P values are indicated; comparisons by Mann-Whitney test.